Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.93 USD | +4.94% | +3.21% | +71.61% |
05-09 | Spyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-02 | Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+71.61% | 1.49B | |
+3.91% | 109B | |
+10.87% | 105B | |
-0.26% | 22.25B | |
-13.14% | 22.09B | |
-8.03% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Piper Sandler Downgrades Aeglea BioTherapeutics to Neutral From Overweight, Cuts Price Target to $1 From $4, Shares Dive 46%